| scholarly article | Q13442814 |
| P356 | DOI | 10.1053/J.AJKD.2009.04.029 |
| P698 | PubMed publication ID | 19577347 |
| P50 | author | Katherine R Tuttle | Q89490767 |
| Daniel C. Cattran | Q116025556 | ||
| P2093 | author name string | Andrew S Levey | |
| Thomas Hostetter | |||
| Bertram Kasiske | |||
| John Sedor | |||
| W Greg Miller | |||
| Aaron Friedman | |||
| P2860 | cites work | Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial | Q44280775 |
| P433 | issue | 2 | |
| P921 | main subject | United States of America | Q30 |
| workshop | Q27556165 | ||
| P304 | page(s) | 205-226 | |
| P577 | publication date | 2009-07-03 | |
| P1433 | published in | American Journal of Kidney Diseases | Q4744250 |
| P1476 | title | Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration | |
| P478 | volume | 54 |
| Q38203370 | 'Progressive diabetic nephropathy. How useful is microalbuminuria?: contra'. |
| Q39678625 | A First-in-Patient, Multicenter, Double-Blind, 2-Arm, Placebo-Controlled, Randomized Safety and Tolerability Study of a Novel Oral Drug Candidate, CTP-499, in Chronic Kidney Disease |
| Q39816520 | A Randomized Phase I Evaluation of CTP-499, a Novel Deuterium-Containing Drug Candidate for Diabetic Nephropathy |
| Q45972129 | A molecular morphometric approach to diabetic kidney disease can link structure to function and outcome. |
| Q84464903 | A proposal for improving the KDIGO renal disease risk table |
| Q37936466 | A review of renal, cardiovascular and mortality endpoints in antihypertensive trials in diabetic patients |
| Q30452095 | Acoustic radiation force impulse imaging for noninvasive evaluation of renal parenchyma elasticity: preliminary findings |
| Q37799323 | Acute kidney injury in childhood: should we be worried about progression to CKD? |
| Q40503443 | Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study |
| Q35210216 | Albuminuria and racial disparities in the risk for ESRD. |
| Q42991610 | Albuminuria risk in Hispanic populations: not so black and white |
| Q44706005 | Albuminuria, proteinuria, and urinary albumin to protein ratio in chronic kidney disease. |
| Q37710377 | Aldosterone: effects on the kidney and cardiovascular system |
| Q47372786 | An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis. |
| Q37369097 | Angiotensin blockade to reduce microvascular damage in diabetes mellitus |
| Q50605578 | Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial. |
| Q24202090 | Antihypertensive agents for preventing diabetic kidney disease |
| Q34483554 | Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: a prospective observational study. |
| Q26863404 | Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis |
| Q39207711 | Assessment of renal tissue elasticity by acoustic radiation force impulse quantification with histopathological correlation: preliminary experience in chronic kidney disease |
| Q36737143 | Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction |
| Q93172593 | Association of diabetic retinopathy and diabetic macular oedema with renal function in southern Chinese patients with type 2 diabetes mellitus: a single-centre observational study |
| Q39373659 | Associations among Serum Beta 2 Microglobulin, Malnutrition, Inflammation, and Advanced Cardiovascular Event in Patients with Chronic Kidney Disease. |
| Q34119963 | Associations of dietary fat with albuminuria and kidney dysfunction |
| Q88635181 | Attitudes and practices of Chinese physicians regarding chronic kidney disease and acute kidney injury management: a questionnaire-based cross-sectional survey in secondary and tertiary hospitals |
| Q36284659 | Biomarkers and surrogate endpoints in kidney disease |
| Q37893446 | Biomarkers in chronic kidney disease: a review |
| Q47423725 | Blood pressure in renal disease: how to accomplish the goal? |
| Q40921568 | Candidate Surrogate End Points for ESRD after AKI. |
| Q44256854 | Cardiovascular Disease Biomarkers and suPAR in Predicting Decline in Renal Function: A Prospective Cohort Study. |
| Q35108899 | Changes in albuminuria predict mortality and morbidity in patients with vascular disease |
| Q34631631 | Chronic kidney disease |
| Q47968630 | Chronic kidney disease and incident apparent treatment-resistant hypertension among blacks: Data from the Jackson Heart Study. |
| Q93063017 | Clinical Impact of a Protocolized Kidney Donor Follow-up System |
| Q90673894 | Clinical significance of contrast-enhanced ultrasound in chronic kidney disease: a pilot study |
| Q37883908 | Combination inhibition of the renin-angiotensin system: is more better? |
| Q90400249 | Comparison of Renal Effects of Ezetimibe-Statin Combination versus Statin Monotherapy: A Propensity-Score-Matched Analysis |
| Q36525946 | Consecutive first-morning urine samples to measure change in the albumin-to-creatinine ratio: a pilot study of a home urine collection protocol |
| Q38537462 | Cost of renal replacement: how to help as many as possible while keeping expenses reasonable? |
| Q90429607 | Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on "The natural history of diabetic kidney disease and treatment of hyperglycemia in patient |
| Q36441616 | Diabetic nephropathy: What does the future hold? |
| Q38203904 | Dipping your feet in the water: podocytes in urine |
| Q35620125 | Diverging association of reduced glomerular filtration rate and albuminuria with coronary and noncoronary events in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. |
| Q37776150 | Dual RAAS blockade is desirable in kidney disease: Con |
| Q34604473 | Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease |
| Q33805412 | Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis |
| Q35025425 | Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset |
| Q37110523 | Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes. |
| Q34408823 | Effect of vitamin-D analogue on albuminuria in patients with non-dialysed chronic kidney disease stage 4-5: a retrospective single center study |
| Q46169904 | Effects of gum arabic (Acacia senegal) on renal function in diabetic mice |
| Q39380540 | Emerging biomarkers of chronic kidney disease in children |
| Q34444944 | End organ damage in hypertension |
| Q53118344 | Expression of TNFRSF6B in kidneys is a novel predictor for progression of chronic kidney disease. |
| Q50281347 | Glomerular Diseases: Registries and Clinical Trials. |
| Q64992038 | Glomerular Hematuria: Cause or Consequence of Renal Inflammation? |
| Q90152926 | Guidelines for clinical evaluation of chronic kidney disease : AMED research on regulatory science of pharmaceuticals and medical devices |
| Q37886063 | Identification and management of albuminuria in the primary care setting |
| Q34281450 | Impact of age and overt proteinuria on outcomes of stage 3 to 5 chronic kidney disease in a referred cohort |
| Q35953248 | Incidence of stroke symptoms among adults with chronic kidney disease: results from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study |
| Q41602365 | Independent correlates of urinary albumin excretion within the normoalbuminuric range in patients with type 2 diabetes: The Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study |
| Q35721420 | Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes |
| Q57312402 | Intensive glucose control improves kidney outcomes in patients with type 2 diabetes |
| Q26822500 | Interplay of vitamin D, erythropoiesis, and the renin-angiotensin system |
| Q36732816 | Investigating kidney donation as a risk factor for hypertension and microalbuminuria: findings from the Swiss prospective follow-up of living kidney donors |
| Q36686998 | Is Bariatric Surgery an Effective Treatment for Type II Diabetic Kidney Disease? |
| Q47128084 | Is Change in Albuminuria a Surrogate Marker for Cardiovascular and Renal Outcomes in Type 1 Diabetes? |
| Q35400901 | Is nocturnal blood pressure reduction the secret to reducing the rate of progression of hypertensive chronic kidney disease? |
| Q34238467 | Kidney function, albuminuria, and all-cause mortality in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study |
| Q52670611 | Kidney injury biomarkers 5 years after AKI due to pediatric cardiac surgery. |
| Q33870550 | Label Free Detection of Sensitive Mid-Infrared Biomarkers of Glomerulonephritis in Urine Using Fourier Transform Infrared Spectroscopy |
| Q44871811 | Mapping of molecular pathways, biomarkers and drug targets for diabetic nephropathy |
| Q26853698 | Measurement of renal function in patients with chronic kidney disease |
| Q90470119 | Microalbuminuria and cardiorenal risk: old and new evidence in different populations |
| Q37259613 | Microalbuminuria in HIV disease |
| Q91651986 | Modifiable Variables Are Major Risk Factors for Posttransplant Diabetes Mellitus in a Time-Dependent Manner in Kidney Transplant: An Observational Cohort Study |
| Q26852459 | Morphologic features of declining renal function in type 1 diabetes |
| Q28748796 | Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy |
| Q37780943 | National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events |
| Q38246640 | New renal drug development to face chronic renal disease |
| Q90651217 | Non-invasive assessment of early stage diabetic nephropathy by DTI and BOLD MRI |
| Q33901914 | Non-invited review: prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD. |
| Q39443166 | Normoalbuminuric diabetic kidney disease |
| Q38763898 | Novel Biomarkers for Renal Diseases? None for the Moment (but One). |
| Q37219032 | Novel therapeutic approaches to chronic kidney disease |
| Q88354441 | Observation period for changes in proteinuria and risk prediction of end-stage renal disease in general population |
| Q37219039 | Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease |
| Q26823206 | Perspectives on systems biology applications in diabetic kidney disease |
| Q26864133 | Present and future in the treatment of diabetic kidney disease |
| Q51277691 | Prevalence of abnormal urinary albumin excretion in elderly people: a Spanish survey. |
| Q38034807 | Prognostic factors in resistant hypertension: implications for cardiovascular risk stratification and therapeutic management. |
| Q37964273 | Prognostic significance and diagnosis of proteinuria in renal transplantation |
| Q35529711 | Prospective Swiss cohort study of living-kidney donors: study protocol |
| Q37446306 | Protective effect of tartary buckwheat on renal function in type 2 diabetics: a randomized controlled trial |
| Q36919041 | Proteinuria as a Therapeutic Target in Advanced Chronic Kidney Disease: a Retrospective Multicenter Cohort Study |
| Q83575095 | Proteinuria as a surrogate end point--more data are needed |
| Q37990717 | Proteinuria should be used as a surrogate in CKD. |
| Q53436478 | Quantitative evaluation of proteinuria for health checkups is more efficient than the dipstick method. |
| Q36334589 | Rate and determinants of association between advanced retinopathy and chronic kidney disease in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study |
| Q41053942 | Recovery of renal function after radical nephrectomy and risk factors for postoperative severe renal impairment: A Japanese multicenter longitudinal study |
| Q44717786 | Reduction and residual proteinuria are therapeutic targets in type 2 diabetes with overt nephropathy: a post hoc analysis (ORIENT-proteinuria). |
| Q55470645 | Relapse or worsening of nephrotic syndrome in idiopathic membranous nephropathy can occur even though the glomerular immune deposits have been eradicated. |
| Q53623538 | Renal acoustic radiation force impulse elastography in the evaluation of coronary artery disease. |
| Q37919547 | Renal endpoints in renal and cardiovascular randomized clinical trials: time for a consensus? |
| Q43156210 | Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial |
| Q34221460 | Renal protection in diabetes: lessons from ONTARGET. |
| Q33750273 | Renal recovery |
| Q38137851 | Renin-angiotensin system blocking drugs. |
| Q36278420 | Repeated treatment with bone marrow cell secretory products maintains long-term renoprotection in experimental chronic kidney disease: a placebo-controlled trial |
| Q50717199 | Residual small artery impairment in hypertensive patients with normal albumin-creatinine ratio. |
| Q40312801 | Role of TGF-alpha in the progression of diabetic kidney disease |
| Q44425937 | Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction |
| Q35817372 | Short-Term High Fat Intake Does Not Significantly Alter Markers of Renal Function or Inflammation in Young Male Sprague-Dawley Rats |
| Q35898292 | Significance of urinary full-length and ectodomain forms of megalin in patients with type 2 diabetes |
| Q36429637 | Soluble Urokinase Receptor and Chronic Kidney Disease. |
| Q39165618 | Subclinical Kidney Damage in Hypertensive Patients: A Renal Window Opened on the Cardiovascular System. Focus on Microalbuminuria. |
| Q34788186 | T/L-type calcium channel blocker reduces the composite ranking of relative risk according to new KDIGO guidelines in patients with chronic kidney disease |
| Q44660764 | Tacrolimus is an alternative therapy option for the treatment of adult steroid-resistant nephrotic syndrome: a prospective, multicenter clinical trial |
| Q37064114 | Temporal trends in the prevalence of diabetic kidney disease in the United States |
| Q37869820 | The goal of blood pressure control for prevention of early diabetic microvascular complications |
| Q38845590 | The next generation of therapeutics for chronic kidney disease |
| Q35924547 | The renal transcriptome of db/db mice identifies putative urinary biomarker proteins in patients with type 2 diabetes: a pilot study |
| Q34346928 | The use of targeted biomarkers for chronic kidney disease |
| Q38098108 | To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease. |
| Q47116963 | Total Kidney Volume Is a Prognostic Biomarker of Renal Function Decline and Progression to End-Stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease |
| Q38160397 | Treatment and impact of dyslipidemia in diabetic nephropathy |
| Q47417726 | Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome |
| Q36100123 | Understanding the mechanisms of proteinuria: therapeutic implications |
| Q38492248 | Update on blood pressure control and renal outcomes in diabetes mellitus |
| Q38258271 | Updating the natural history of diabetic nephropathy |
| Q47783568 | Urinary Smad1 is a new biomarker for diagnosis and evaluating the severity of diabetic nephropathy |
| Q36206158 | Urinary matrix metalloproteinase activity in diabetic kidney disease: a potential marker of disease progression |
| Q36389219 | Urine podocin:nephrin mRNA ratio (PNR) as a podocyte stress biomarker |
| Q37340215 | Urine podocyte mRNAs, proteinuria, and progression in human glomerular diseases |
| Q90198304 | Usefulness of the quantitative measurement of urine protein at a community-based health checkup: a cross-sectional study |
| Q37721287 | When to initiate ACEI/ARB therapy in patients with type 1 and 2 diabetes |
| Q47574912 | Why does quality of life remain an under-investigated issue in chronic kidney disease and why is it rarely set as an outcome measure in trials in this population? |
| Q35179914 | initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial |
Search more.